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Abstract
Background: Cryptic structural abnormalities within the subtelomeric regions of chromosomes
have been the focus of much recent research because of their discovery in a percentage of people
with mental retardation (UK terminology: learning disability). These studies focused on subjects
(largely children) with various severities of intellectual impairment with or without additional
physical clinical features such as dysmorphisms. However it is well established that prevalence of
schizophrenia is around three times greater in those with mild mental retardation. The rates of
bipolar disorder and major depressive disorder have also been reported as increased in people with
mental retardation. We describe here a screen for telomeric abnormalities in a cohort of 69
patients in which mental retardation co-exists with severe psychiatric illness.
Methods: We have applied two techniques, subtelomeric fluorescence in situ hybridisation (FISH)
and multiplex amplifiable probe hybridisation (MAPH) to detect abnormalities in the patient group.
Results: A subtelomeric deletion was discovered involving loss of 4q in a patient with co-morbid
schizoaffective disorder and mental retardation.
Conclusion: The precise region of loss has been defined allowing us to identify genes that may
contribute to the clinical phenotype through hemizygosity. Interestingly, the region of 4q loss
exactly matches that linked to bipolar affective disorder in a large multiply affected Australian
kindred.
Background
The isolation of unique DNA probes from the sub-telom-
eric regions of all chromosomes has opened up a field of
cytogenetics research that was previously inaccessible to
conventional karyotyping protocols [1]. Since then a
number of studies have shown that cryptic structural
abnormalities (deletions, duplications etc.) in the subte-
lomeric regions are relatively commonly found in groups
of individuals with idiopathic mental retardation (UK;
learning disability; LD). The biological attributes of these
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The frequency of meiotic recombination is at its highest at
the ends of chromosomes (recently confirmed in the Ice-
landic microsatellite map of the human genome [2]).
Therefore errors in this process should randomly result in
a greater frequency of unbalanced chromosome rear-
rangement products at telomeres. There also appears to be
a greater density of genes at the ends of some chromo-
somes, especially those with non-staining R-bands. Thus,
any telomeric copy number change is likely to affect sev-
eral genes; potentially resulting in clinical features typical
of a contiguous gene syndrome – dysmorphisms, devel-
opmental delay and mental retardation. A number of
reports have now shown that 0.5%–23% of idiopathic
mental retardation cases are associated with cryptic trans-
locations in the vicinity of chromosome telomere (see [3-
17] and [18] for a recent review).
FISH, using a commercially available set of subtelomeric
probes is the most commonly used screening technique
[19,20]. Variations on the theme of FISH (e.g. SKY and
CGH) have also been employed. More recently, methods
that rely on the detection of copy number changes at sub-
telomeric loci have been described. MAPH [21-24] is one
such technique in which probes are representatively
amplified by the polymerase chain reaction following
hybridisation to a patient's genomic DNA sample to gen-
erate a quantitative profile of subtelomeric sequence copy
number.
Psychiatric disorders such as schizophrenia (SCZ) and
bipolar affective disorder (BPAD) are relatively common
in the general population and there is much evidence for
a genetic component to susceptibility (for a review see
[25]). However, it is clear from the lack of consistent find-
ings from linkage mapping and association studies that
they are likely to be complex and aetiologically heteroge-
neous disorders. For example, several genes might act
simultaneously (oligogenic action) or interact (epistasis)
to produce the clinical phenotype in any individual, and
those genes might be different in different individuals
(locus heterogeneity). An alternative to cohort based link-
age and association approaches uses cytogenetic abnor-
malities as direct pointers to candidate gene loci and this
has been successfully applied to patients with psychiatric
disorders resulting in the identification of a number of
candidate susceptibility genes including DISC1/DISC2
[26], DIBD1 [27] and GRIA3 [28]. The chromosome
abnormalities that disrupted these genes were reciprocal
translocations visible by standard cytogenetic methods.
The risk of schizophrenia and affective disorders in
patients with idiopathic mild mental retardation is signif-
icantly raised and it is well established that schizophrenia
is three times more common in this group than the gen-
eral population and that there is a strong familial element
[29]. Both bipolar illness and major depressive disorder
have also been described as of increased prevalence in the
population with mild mental retardation. The study also
revealed a previously undetected complex re-arrangement
between chromosomes 2 and 11, and a case of trisomy X,
but did not address subtelomeric changes. It strongly sug-
gested however that the co-association between mental
retardation and schizophrenia is highly familial with
greater rates of both schizophrenia and co-morbid schizo-
phrenia/mental retardation occurring in the families of
co-morbid probands compared to families of probands
with schizophrenia alone or with mental retardation
alone. Limbic system (amygdalo-hippocampal) neuropa-
thology is especially pronounced in this group [30]. We
have formed the hypothesis that patients who are co-mor-
bid for severe psychiatric illness and mental retardation
may be homogenous in their pathophysiology and that,
in addition to large-scale structural chromosomal abnor-
malities, they may harbour as yet undetected cryptic telo-
meric changes. To test this we have screened a series of 69
patients co-morbid for mental retardation and psychiatric
illness using fluorescence in situ hybridisation (FISH) and
multiplex amplifiable probe hybridisation (MAPH).
Methods
Patient Cohort
Local research ethics permission was obtained for this
study. The patients were initially ascertained through
computerised psychiatric clinical case-registers that
allowed us to identify adults with dual diagnosis of psy-
chosis and mental retardation. A specific psychiatry serv-
ice exists in Scotland to meet the needs of patients with
mental retardation who also suffer from psychiatric disor-
ders and initial clinical diagnoses were confirmed by con-
sultation between the relevant specialist clinician
involved and the research team member who is also a spe-
cialist in the psychiatry of mental retardation (WM). Con-
firmation that IQ fell within the mild range of mental
retardation was obtained from case records.
69 patients with mild mental retardation (IQ 70 to
around 50) and a referral diagnosis of co-existing schizo-
phrenia or major affective disorder were studied. Parental
samples were not available in many cases due to the age
of the probands. This cohort is a subset of 74 originally
ascertained subjects: 5 were removed because of aneu-
ploidy (2 cases of 47(XXX)) or after more thorough psy-
chiatric evaluation. One discounted subject with only
mental retardation possessed a 6q subtelomeric deletion
as determined by several MAPH probes (data not shown).
The lifetime version of the Schedule for Affective Disor-
ders and Schizophrenia (SADS-L [31]) along with exten-
sive case record review, and interviews with key carers and
relatives was used to gather the information needed toPage 2 of 7
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according to the Diagnostic and Statistical Manual 4th Edi-
tion (DSM-IV [32]). Diagnosis was finalised by consensus
between two experienced psychiatrists (DB, WM) one of
whom specialises in the psychiatry of mental retardation
(WM). SADS-L has previously been successfully used in
people with mild mental retardation [29] to establish psy-
chiatric diagnoses.
Overall 49 subjects met the DSM-IV criteria for definite
schizophrenia, 3 for schizoaffective disorder, 11 for Bipo-
lar I Disorder, 1 for recurrent Major Depressive Disorder
(unipolar depression). In addition, 5 subjects were diag-
nosed as having a unspecified functional psychosis (DSM-
IV 298.9, Psychotic disorder NOS).
None had co-existing Down Syndrome or Fragile X disor-
der. A breakdown of the patients into their clinical catego-
ries and methodology of screening is presented in table 1.
DNA extraction
DNA was extracted from venous blood samples (10 mls)
of all patients by standard methods using Nucleon BACC2
kits (Nucleon Biosciences). 1 mg/ml dilutions were pre-
pared for MAPH.
MAPH
All 57 MAPH samples were tested in triplicate using the
subtelomeric screening set described previously [23]. All
samples were anonymised prior to MAPH analysis. Each
sample was tested three times, and putative positives iden-
tified by a univariate method (standard hypothesis testing
against a normal distribution) and multivariate methods
employed by the software SYSTAT 8.0 (Bivariate scatter-
graphs and Hadi outlier analysis). Four putative positives
were divided into one confident (univariate analysis, p <
0.01, corrected for multiple observations) and three pos-
sible (univariate analysis, p < 0.05, corrected for multiple
observations, Hadi outlier distance >4, all three results
reporting a consistent change: either all >1.0 or <1.0) pos-
itive results. The three "possible" positives have since been
discounted since they involved gain of the 20p telomeric
probe ST18E1, which from experience with normal con-
trol subjects has shown to have unacceptably high meas-
urement error. This probe has been replaced in more
recent formulations of the subtelomeric probe set.
Subtelomeric FISH
Blood samples from a subset of the patients were cultured
in Peripheral Blood Medium (Sigma) for 72 hours. After
colcemid treatment for one hour, lymphocytes were lysed
and fixed in methanol:acetic acid (3:1). Fixed metaphase
material was dropped onto microscope slides. Each slide
was hybridised by three fluorescently labelled probe
mixes (ToTelVysion, Vysis Inc.) under separate coverslips.
All 15 mixes covering every subtelomeric region for a
patient could thus be analysed on 5 slides. Images were
captured on a Zeiss Axioskop2 microscope coupled to a
Macintosh G4 computer running SmartCapture2.1 soft-
ware (Digital Scientific). Five metaphases were scored for
each probe mix.
Results
A subtelomeric deletion identified in one subject
Complete accord was seen in the 12 instances where both
screening methodologies were used. The FISH approach
did not detect any subtelomeric abnormalities (including
balanced translocations, which would not be observable
by MAPH). However, MAPH identified a subject with a
loss of one copy of the 4q subtelomeric region (p < 1 × 10-
3, corrected for multiple observations). It is unlikely that
this copy number change (4q-) defined by MAPH repre-
sents an irrelevant polymorphism; no similar change was
found on analysis of 83 unrelated control individuals, giv-
ing an upper (95% confidence) limit of 1.6% for the fre-
quency of this variant.
Precise definition of 4q loss
Additional MAPH probes were designed to determine the
extent of the 4q deletion (fig. 1). The results show that the
proximal boundary of the subtelomeric deletion is
between the FAT gene and the proximal end of clone
Table 1: Subject classification and analysis Breakdown of subjects into their diagnostic categories and applied experimental 
methodology. MR; mental retardation, SCZ; schizophrenia, BP1; bipolar affective disorder I, SCAFF; schizoaffective disorder, UFP; 
unspecified functional psychosis, UPR; unipolar depression.
Clinical category MAPH alone MAPH and FISH FISH alone
MR/SCZ 34 7 8
MR/BP1 6 3 2
MR/SCAFF 1 2 0
MR/UFP 3 0 2
MR/UPR 1 0 0
TOTAL SCREEN 45 12 12Page 3 of 7
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ues for boundary probes (Ho, value = 1.00), p < 5 × 10-5
for deletion and p > 0.05 for normal dosage. This 4q dele-
tion encompasses a region of annotated genomic DNA of
approximately 3 Mb. The transcript map of this region is
not yet completely defined (see Table 2) but contains at
Subtelomeric region of chromosome 4qFigure 1
Subtelomeric region of chromosome 4q Only annotated, unique chromosome sequence is shown, derived from the 
November 2002 version of the UCSC Human Genome assembly (subtelomeric repeats would extend to the right of the dia-
gram). A scale bar and the gene content (see Table 2) of the region are shown. The positions of the MAPH markers are also 
shown which allowed the maximum and minimum extents of the deletion to be defined (black bar). Above the chromosome 
region is shown the result of duplicate analysis from each MAPH probe (mean +/- 95% CI), together with the 3 standard devi-
ation threshold and the results from the other control probes (mean +/- 95% CI).
Table 2: Gene content of 4q deletion Genes/putative transcriptional units within the deleted region on chromosomes 4q. ESTs a-f are 
represented in figure 1. An attempt to gauge the approximate expression levels of each gene was based on the number of EST clones 
present in the UCSC Human Genome Browser (Nov.2002/Apr.2003 releases). A brief summary of gene function and a representative 
accession number, where informative, is also included. TUBB4Q (4q35) is omitted from this list because it is a confirmed pseudogene.
4q35 GENE EST exp. Function/comments
FAT ++++ Cadherin-related tumor suppressor homologue precursor
EST a + (BE856720) Novel.
EST b + (BM806339) Novel. Contains 5 1/2 copies of 34aa repeat motif
EST c ++ (AI917275) Novel. No obvious ORF
ZFP42/FLJ32157 + (AK056719) Similar to transcriptional repressor protein YY1
FLJ25801 + (AK098667) Protein contains SMC (chromosome segregation ATPase) domain and PRY/SPRY domains 
(unknown function).
EST d +++ (BU571187) Novel.
EST e + (BC033535) Novel.
EST f + (BC029568) LOC256307 novel predicted gene
FRG1 ++++ Facioscapulohumeral muscular dystrophy region gene 1
DUX4 + Homeobox protein, multiple copies.Page 4 of 7
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authenticity/experimental evidence attached to each one.
Discussion
Unlike simple chromosomal translocations, large dele-
tions associated with a certain condition can present
many candidate genes for further study. In the context of
psychiatric disorders velo-cardio-facial syndrome (VCFS
or del22q11 syndrome) offers a model of how a cryptic
deletion associated with schizophrenia has highlighted
several candidate genes for future study [33-35].
We used two methods to screen for subtelomeric changes
in our cohort of patients. The MAPH technique has
proved a fast and accurate method for determining copy
number changes in the human genome and represents a
cost-effective route to the screening of large numbers of
patients. In addition, the disorders that can be studied by
this approach are limited only by the design of suitable
primers so that screening for both single and contiguous
gene disorders is feasible. MAPH has also been proved to
be a simple method to map deletion breakpoints with
greater resolution than FISH. The subtelomeric FISH
approach is a more demanding approach because of the
patient sample preparation, the requirement for special-
ised microscopy equipment, the cost of the commercial
probe sets and the labour involved. Nevertheless, FISH
has some advantages: the FISH approach is the only way
to detect balanced chromosome rearrangements such as
inversions and translocations. Other studies of subtelom-
eric regions in mental retardation subjects have identified
such chromosomal aberrations. In addition, FISH has
been a vital technique for identifying disrupted genes such
as DISC1 in psychiatric patients with (non-subtelomeric)
chromosomal rearrangements. Therefore, the selection of
the screening technique should be determined by the
number of cases to be studied and the nature of the abnor-
malities expected.
We have identified a subtelomeric deletion within our
cohort of 69 patients using the MAPH and FISH method-
ologies. This 4q deletion is associated with a co-morbid
phenotype of schizoaffective disorder and mild mental
retardation (fullscale IQ between 60 and 70). Consent
was not forthcoming to determine whether the deletion
was of parental or de novo origin. However, psychiatric ill-
ness has not been diagnosed in other members of the fam-
ily. We cannot, therefore, formally link the presence of the
deletion with mental retardation and/or psychiatric ill-
ness in the patient. The annotation of transcripts at
4q35.2 is currently an active area of research (see fig. 1 and
table 2) because of good linkage evidence (LOD score of
3.2 for microsatellite marker D4S1652) from an extended
Australian kindred multiply affected with bipolar affective
disorder [36-38]. Importantly, the principal linkage
region almost exactly matches the deletion interval
observed in our patient. The 4q deletion patient has been
diagnosed with schizoaffective disorder (DSM-IV 295.7) –
with periods of psychotic depression but also mood
incongruent hallucinations and delusions. This is in con-
trast to the clear bipolar affective disorder diagnosed for
members of the described linkage family. However, it has
been repeatedly observed that schizoaffective disorders
and bipolar affective disorders overlap clinically and are
indeed often difficult to separate. One postulated explana-
tion for the now frequently reported linkage overlaps
between bipolar illness, schizoaffective disorders and
schizophrenia is that the inherited susceptibility is for psy-
chosis rather than a specific disorder (reviewed in [39]).
The subtelomeric region of 4q is also interesting because
it contains a candidate gene, FRG1, for facioscapulo-
humeral muscular dystrophy. The 4q patient does not
show any of the typical features of this disorder but this
can be explained by the fact that copy number does not
appear to be critical for the onset of the disorder [40].
Rather, the proximity of the gene to a variable number tel-
omeric repeat sequence (D4Z4) seems to be the chief
determinant of pathology [41].
Of the 69 patients with clear co-morbidity, one (1.4%)
possessed a single copy subtelomeric deletion. This fre-
quency is in line with those from studies of individuals
with mental retardation alone [18]. As more studies exam-
ine chromosomal integrity in people with mental retarda-
tion or other conditions we hope that replication of
subtelomeric abnormalities will be observed, perhaps
leading to the eventual clinical definition of range of 'sub-
telomeric syndromes' such as that recently described for
the subtelomeric deletion of 1q [42].
Conclusions
The identification of the precisely delimited 4q deletion
may contribute to the mapping of the susceptibility gene
for psychiatric illness at this locus. The finding of bipolar
affective disorder linkage to this region suggests that, in
this case at least, the schizoaffective and mental retarda-
tion components to the co-morbid phenotype may be dis-
crete and genetically separable in the manner of other
contiguous gene disorders. If it is assumed that either
component of the clinical phenotype is caused by hap-
loinsufficiency then examining the comparative
expression levels of candidate genes in normal, bipolar-
linked and 4q deleted lymphoblastoid cell lines might
provide a quick route to the identification of causative
genes. Alternatively, gene association studies may be
required to identify the candidate psychiatric illness gene
at 4q35. The high rate of recombination in subtelomeric
DNA means that a higher density of genetic markers will
be required to establish linkage or association reliably;Page 5 of 7
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